Allarity Therapeutics Says FDA Granted Fast-Track Designation to Stenoparib; Shares Rise Pre-Bell

MT Newswires Live

08/26

Allarity Therapeutics (ALLR) said Tuesday that the US Food and Drug Administration has granted fast-track designation to stenoparib, the company's investigational treatment for patients with advanced ovarian cancer.

Shares of the company rose more than 36% in recent Tuesday premarket activity.

The fast track designation enables expedited development and review of drugs that are intended to treat serious conditions and fill an unmet medical need, the company said.

Price: 1.24, Change: +0.32, Percent Change: +33.86

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2562779735"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562779735\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562779735?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562779735","market":"fut","top_or_hot":-1,"title":"Allarity Therapeutics Says FDA Granted Fast-Track Designation to Stenoparib; Shares Rise Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Allarity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ALLR) said Tuesday that the US Food and Drug Administration has granted fast-track designation to stenoparib, the company's investigational treatment for patients with advanced ovarian cancer.</p><p>Shares of the company rose more than 36% in recent Tuesday premarket activity.</p><p>The fast track designation enables expedited development and review of drugs that are intended to treat serious conditions and fill an unmet medical need, the company said.</p><p>Price: 1.24, Change: +0.32, Percent Change: +33.86</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allarity Therapeutics Says FDA Granted Fast-Track Designation to Stenoparib; Shares Rise Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllarity Therapeutics Says FDA Granted Fast-Track Designation to Stenoparib; Shares Rise Pre-Bell\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-08-26 20:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Allarity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ALLR) said Tuesday that the US Food and Drug Administration has granted fast-track designation to stenoparib, the company's investigational treatment for patients with advanced ovarian cancer.</p><p>Shares of the company rose more than 36% in recent Tuesday premarket activity.</p><p>The fast track designation enables expedited development and review of drugs that are intended to treat serious conditions and fill an unmet medical need, the company said.</p><p>Price: 1.24, Change: +0.32, Percent Change: +33.86</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2562779735","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562779735","pubTimestamp":1756210551,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Allarity Therapeutics  said Tuesday that the US Food and Drug Administration has granted fast-track designation to stenoparib, the company's investigational treatment for patients with advanced ovarian cancer.Shares of the company rose more than 36% in recent Tuesday premarket activity.The fast track designation enables expedited development and review of drugs that are intended to treat serious conditions and fill an unmet medical need, the company said.Price: 1.24, Change: +0.32, Percent Change: +33.86","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ALLR":"Allarity Therapeutics Inc","LENZ":"Therapeutics","BK4588":"碎股","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","BK4539":"次新股","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","ALLR.AU":"ARISTOCRAT RTS FORUS","BK4139":"生物科技","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4104":"贸易公司与经销商","FAST":"快扣"},"translate_title":"Allarity Therapeutics表示FDA授予Stenoparib快速通道资格；盘前股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLR":0.9,"ALLR.AU":1,"FAST":1,"LENZ":1},"content_text":"Allarity Therapeutics (ALLR) said Tuesday that the US Food and Drug Administration has granted fast-track designation to stenoparib, the company's investigational treatment for patients with advanced ovarian cancer.Shares of the company rose more than 36% in recent Tuesday premarket activity.The fast track designation enables expedited development and review of drugs that are intended to treat serious conditions and fill an unmet medical need, the company said.Price: 1.24, Change: +0.32, Percent Change: +33.86","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}